Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ) Sees Q2 Revenues, Profits Drop But Beats Expectations

Page 1 of 2

Johnson & Johnson (NYSE:JNJ) reported a drop in sales and earnings for the second quarter of fiscal year 2015 on Tuesday, but still managed to beat Wall Street expectations on both counts. According to the firm, adjusted net earnings and diluted earnings per share for the quarter were $4.81 billion and $1.71 respectively, down by 6.3% and 3.9% year-over-year. Revenues stood at $17.79 billion, down by 8.8% compared to the second quarter of 2014. Analysts were expecting an EPS of $1.67 on revenues of $17.75 billion. Johnson & Johnson is pointing to the strong U.S dollar contributing to its slide in sales and profits. While international sales did fall drastically, by 14.3%, reflecting the negative currency impact of 14.8%, domestic sales also slumped by 2.4%. Sales to customers in nearly all segments except for consumer sales in the U.S. were down year-over-year. By geographic area, all sales for the second quarter experienced a decline. It should be noted, however, that Johnson & Johnson (NYSE:JNJ) has increased its adjusted earnings guidance for the full 2015 fiscal year to between $6.10 and $6.20 per share, excluding after-tax intangible amortization expense and special items. Alex Gorsky, chairman and chief executive officer, remained upbeat, saying in a statement that, “Our solid sales and earnings results in the quarter reflect the strong underlying growth we’re seeing across the enterprise.”

Johnson & Johnson JNJ headache tylenol pain acetaminophen pill relief display health

Niloo /

Nonetheless, Wall Street has reacted negatively to the Johnson & Johnson (NYSE:JNJ) slide in earnings and revenues, as the stock has fallen by 0.61% in morning trading to $99.69. Year-to-date, the stock has fallen by 4.86%. Hedge fund sentiment based on our database of over 700 hedge funds is slightly bearish. The value of shares collectively held by the funds we track decreased by 8.13% in the first quarter to $4.58 billion, though that was slightly attributable to the 3.8% share price decline in the first quarter. Meanwhile, 77 hedge funds had long positions in Johnson & Johnson (NYSE:JNJ) by the end of the first three months of the year, compared to 76 hedge funds at the end of the previous quarter.

Hedge funds and other big money managers tend to have the largest amounts of their capital invested in large and mega-cap stocks like Johnson & Johnson because these companies allow for much greater capital allocation. That’s why if we take a look at the most popular stocks among funds, we won’t find any mid- or small-cap stocks there. However, our backtests of hedge funds’ equity portfolios between 1999 and 2012 revealed that the 50 most popular stocks among hedge funds underperformed the market by seven basis points per month, showing that their most popular picks and the ones that received the bulk of their capital were not actually their best picks. On the other hand, their top small-cap picks performed considerably better, outperforming the market by 95 basis points per month. This was confirmed through backtesting and in forward tests of our small-cap strategy since August 2012. The strategy, which involves imitating the 15 most popular small-cap picks among hedge funds has provided gains of more than 135%, beating the broader market by over 80 percentage points through the end of April (see the details).

At Insider Monkey, we also follow company insiders to see whether these insiders have recently purchased or sold stock in their companies. This tells us if company insiders are willing to risk their money on their firm’s stock or whether they are cashing in. Director Charles Prince bought 2,500 shares of the company on June 2. However, Chief Scientific Officer Paulus Stoffels sold 187,250 shares on April 28.

Considering all of this, let’s check out the fresh hedgie activity surrounding Johnson & Johnson.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!